On a GLP-1 medication, weight loss unfolds gradually over more than a year — not in a few dramatic weeks. Most people begin on a deliberately low dose that steps up roughly every four weeks. Appetite and background "food noise" usually quiet within the first month; early nausea tends to ease as the body adjusts; the steadiest loss comes in months three to six as the dose reaches its target; and in the pivotal trials the bulk of weight loss landed around 68 to 72 weeks — roughly 12 to 18 months — before slowing to a plateau. That plateau is your body defending a new set point, not a sign the medication has failed.
This is a realistic, trial-based map of that journey. It is background information, not medical advice: which drug, which dose, and how fast to move are decisions your prescriber makes for you. For the wider picture of how these drugs work, who they are for, and how they compare, start with our complete GLP-1 guide and the weight & metabolism hub. The month-by-month arc below is tied closely to the dose titration schedule, so the two are worth reading together.
The month-by-month GLP-1 timeline at a glance
Semaglutide (Wegovy) and tirzepatide (Zepbound) both start low and climb in steps to let the gut adapt. The table below shows the typical phases. Your own numbers will differ — the percentages are trial averages, and individual variation is large.
| Phase | What's happening in your body | What's typical | What to watch for |
|---|---|---|---|
| Weeks 1–4 (starting dose) | The lowest dose is used purely to let your gut adjust — it is not meant to drive big weight loss yet. Appetite signals begin to shift and "food noise" often quiets. | Feeling full faster, less preoccupation with food, and often a small early drop of a few pounds. | Mild nausea, constipation, or reflux that usually eases with smaller, slower meals and fluids. |
| Months 1–2 (dose steps up) | The dose increases about every four weeks along the schedule your prescriber follows. Each step raises the drug's effect. | Appetite noticeably lower; many people have lost in the low single-digit percentages by now. | A brief flare of GI side effects can follow each increase, then settle. Stay hydrated if vomiting or diarrhea occur. |
| Months 3–6 (reaching target dose) | You reach a maintenance dose. This is usually the steadiest, most visible phase of loss. | Often the bulk of noticeable weight change; energy and eating habits settle into a rhythm. | Muscle loss if protein and strength work are neglected; rarely, gallbladder pain. |
| Months 6–18 (approaching peak) | Loss continues but slows. In trials, average weight kept falling until roughly 68–72 weeks. | STEP 1 averaged ~15% at 68 weeks; SURMOUNT-1 averaged up to ~21% at 72 weeks on the highest dose. | A slowing scale (normal), and sometimes temporary hair shedding. |
| Plateau & maintenance | Weight stabilizes as the body defends a new, lower set point. The medication now helps hold the loss. | Maintenance rather than continued loss — this is the goal, not a failure. | Weight tends to return if the drug is stopped without a plan; discuss any dose changes with your prescriber. |
The first few weeks: appetite quiets before the scale moves
GLP-1 medicines are started at a low "initiation" dose on purpose. That first dose is chosen for tolerability, not maximum weight loss, which is why the scale may barely move in weeks one to four. What many people notice first is not a lower number but a quieter head: less constant thinking about food, feeling satisfied sooner, and losing interest partway through a meal. Researchers describe this as reduced "food noise."
Early gastrointestinal side effects — nausea, fullness, constipation, occasional reflux — are common in this window and are usually mild to moderate. In STEP 1, nausea and diarrhea were the most frequent complaints, were typically transient, and subsided over time. Smaller portions, eating slowly, and stopping at the first sign of fullness all help. Our guide to Ozempic and Wegovy side effects covers what tends to ease on its own and what deserves a call to your clinician.
Months one to two: the dose climbs and the first pounds come off
After the initiation period, the dose steps up at intervals of about four weeks. Each increase can bring a short new wave of GI symptoms that usually settles within days as your body re-adapts — one reason prescribers move slowly rather than rushing to the top dose. By the end of the second month many people have lost weight in the low single-digit percentages, though the range is wide.
A women's-health note on contraception: tirzepatide (Mounjaro, Zepbound) can reduce the effectiveness of oral birth control pills around the time it is started and after each dose increase, because it slows stomach emptying. Semaglutide does not carry this warning. If this applies to you, read GLP-1 medications and birth control and raise it with your prescriber before starting.
Months three to six: steadier loss as the dose reaches target
Once you settle onto a maintenance dose, most people enter the most productive stretch. Appetite regulation is at full effect, habits have caught up, and the weekly numbers become more predictable. This is also the phase where how you lose weight starts to matter as much as how much. A meaningful share of any rapid weight loss can be lean muscle, and protecting muscle is what keeps your metabolism and strength intact — especially for women in midlife, who are already losing muscle to age and shifting hormones.
Prioritizing protein at every meal and doing regular resistance work makes a real difference here. See GLP-1 medications and muscle loss, strength training for women, and how much protein women actually need. These are not extras — they are what turns weight loss into a healthier body composition.
Months six to eighteen: where most of the weight actually lands
The single most misunderstood part of the timeline is how long it takes. In the landmark trials, average weight was still declining well past a year. In STEP 1, adults on once-weekly semaglutide 2.4 mg lost an average of 14.9% of body weight by week 68 (about 15.5 months). In SURMOUNT-1, adults on tirzepatide lost an average of about 15% to 21% by week 72 (about 16.5 months), depending on dose. Both curves flattened only as they approached those endpoints.
The practical takeaway: judging the medication at month three, or expecting the fast losses seen in the first weeks to continue indefinitely, sets you up to quit too early. The trials measured their headline results at roughly 12 to 18 months of continuous treatment at the full dose. Progress genuinely slowing after a strong start is the expected shape of the curve, not a stall you did something wrong to cause.
The plateau: a new set point, not a failure
Eventually weight loss slows and then stops. This plateau is one of the most demoralizing moments for people who don't expect it — and one of the most normal. As you lose weight, the body defends itself: it lowers energy expenditure, raises hunger signals, and blunts fullness signals to pull you back toward a defended weight. The Obesity Medicine Association and other clinical bodies frame this through set-point biology — a key reason obesity behaves as a chronic, relapsing condition that is managed rather than cured. Reaching a plateau means your body has found a new, lower equilibrium; the medication's job then shifts from driving loss to helping you hold it.
What to do at a plateau
First, reframe it: a plateau at a healthier weight, sustained, is a successful outcome — not a problem to attack with crash dieting, which usually costs muscle and backfires. Sensible steps, most of which involve a conversation with your clinician rather than anything you do on your own:
- Protect muscle. Keep protein high and keep doing resistance training so the weight you keep off is fat, not lean tissue. This also supports resting metabolism.
- Check the basics. Sleep, alcohol, stress, and steady movement all influence appetite and weight regulation.
- Let your prescriber review the dose. If you plateaued below the maximum dose, a clinician may consider adjusting it, or discuss whether a different medication fits you better. This is a prescriber-led decision — never self-adjust, and never source or self-dose medication outside a licensed prescriber.
- Set realistic expectations with the tool. Our GLP-1 weight-loss projector shows how trial-based ranges might look for someone like you, so a plateau reads as expected biology rather than personal failure.
What happens if you stop
Because these drugs treat a chronic condition, stopping usually reverses their effect. In the STEP 1 extension, participants regained about two-thirds of the weight they had lost within a year of stopping semaglutide, and much of the improvement in blood pressure and blood sugar reversed alongside it. Average weight stayed somewhat below where people started, but the trajectory was clearly upward once the medication was gone. This is not a willpower problem — it is the same set-point biology reasserting itself.
That is why any decision to stop, pause, or taper should be planned with your clinician, ideally with a maintenance strategy in place. Read what happens when you stop a GLP-1 and GLP-1 weight regain for what the evidence shows and how people manage transitions.
Your timeline will not look exactly like the averages
Every figure above is an average across thousands of people. Real individual results scatter widely: some people lose more and faster, some plateau earlier, some tolerate the climb easily and others need extra time at each step. Age, starting weight, the specific drug and dose, muscle mass, other medications, and genetics all shape the curve. If your journey doesn't match a chart online, that is normal — compare yourself to your own starting point, not to someone else's before-and-after. For women navigating this alongside perimenopause and menopause, our piece on GLP-1s and menopause-related weight gain adds context specific to midlife.
When to see a doctor
Most GLP-1 side effects are mild and fade. Some are not. Seek prompt medical care if you experience:
- Severe or persistent abdominal pain, especially pain that radiates to the back or comes with vomiting — this can signal pancreatitis and needs urgent evaluation.
- Signs of gallbladder trouble: intense upper-right abdominal pain, fever, or yellowing of the skin or eyes.
- Persistent vomiting or diarrhea with signs of dehydration, which can also affect kidney function.
- A lump or swelling in the neck, hoarseness, or trouble swallowing (rare; discuss your personal and family thyroid history with your prescriber before starting).
- Signs of a severe allergic reaction, such as swelling or difficulty breathing — call emergency services.
If nausea or other side effects are simply making the medication hard to live with, that too is worth a call — dose timing and pace can often be adjusted. To connect the whole picture, revisit the GLP-1 guide, the dosing schedule, and the semaglutide drug page, or use the eligibility checker and find-care directory to start a conversation with a clinician.
